Drugs / PAMVATAMIG
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06015568 | Sep 2023 → Nov 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07448116 | Jan 2026 → Feb 2029 expected | cancer | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04930432 | Sep 2021 → Apr 2028 expected | colorectal cancer, head and neck cancer, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04868877 | Apr 2021 → Mar 2026 overdue | colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma +1 | Merus B.V. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06885840 | Mar 2025 → Apr 2028 expected | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Betta Pharmaceuticals Co., Ltd. | Results 2025WCLC丨MCLA-129治疗NSCLC患者1期研究更新结果发布 bettapharma.com ↗
MCLA-129 双特异性抗体在晚期 NSCLC 患者，尤其是在具有 METex14 、 EGFR exon20ins 和 non-exon20ins 突变的患者中展示了 初步 可观 的 疗效和可控的安全性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Betta Pharmaceuticals Co., Ltd. | 2025WCLC丨MCLA-129治疗NSCLC患者1期研究更新结果发布 bettapharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAMVATAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314862 ↗ |
| Known as | MCLA-129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04930432 ↗ |
| Action | Inhibit | “simultaneously blocking the signaling pathways of both EGFR and c-Met” NCT07448116 ↗ |
| Modality | Monoclonal antibody | “full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET” NCT04868877 ↗ |
| Route | Intravenous | “Participants will receive intravenous infusion of MCLA-129 every two weeks” NCT04868877 ↗ |
| Target | EGFR | “full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET” NCT04868877 ↗ |
| Target | MET | “full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET” NCT04868877 ↗ |